复宏汉霖HLX11正式获得美国FDA批准上市

南方财经网
Nov 17

  南方财经11月17日电,复宏汉霖HLX11(帕妥珠单抗,美国商品名:POHERDY®)正式获得美国FDA批准上市,用于HER2阳性乳腺癌的治疗。这是美国首个帕妥珠单抗生物类似药,也是FDA批准的首款用于治疗癌症的可互换生物类似药。此外,HLX11也已在中国、欧洲和加拿大递交上市申请并获受理。截至目前,复宏汉霖已有7款产品于海外获批上市,其中4款产品在美国获批上市。(21世纪经济报道)

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10